120 related articles for article (PubMed ID: 21824820)
1. Prevention of T cell activation by interference of internalized intravenous immunoglobulin (IVIg) with MHC II-dependent native antigen presentation.
Aubin É; Proulx DP; Trépanier P; Lemieux R; Bazin R
Clin Immunol; 2011 Dec; 141(3):273-83. PubMed ID: 21824820
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg).
Paquin Proulx D; Aubin E; Lemieux R; Bazin R
Clin Immunol; 2010 Jun; 135(3):422-9. PubMed ID: 20138586
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells, but not macrophages or B cells, activate major histocompatibility complex class II-restricted CD4+ T cells upon immune-complex uptake in vivo.
de Jong JM; Schuurhuis DH; Ioan-Facsinay A; Welling MM; Camps MG; van der Voort EI; Huizinga TW; Ossendorp F; Verbeek JS; Toes RE
Immunology; 2006 Dec; 119(4):499-506. PubMed ID: 16995881
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway.
Rock KL; Clark K
J Immunol; 1996 May; 156(10):3721-6. PubMed ID: 8621907
[TBL] [Abstract][Full Text] [Related]
5. Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response.
Zhou G; Ding ZC; Fu J; Levitsky HI
J Immunol; 2011 Feb; 186(4):2148-55. PubMed ID: 21242518
[TBL] [Abstract][Full Text] [Related]
6. Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens.
Chung Y; Chang JH; Kim BS; Lee JM; Kim HY; Kang CY
Eur J Immunol; 2007 Jun; 37(6):1453-62. PubMed ID: 17474148
[TBL] [Abstract][Full Text] [Related]
7. IVIg-mediated inhibition of antigen presentation: predominant role of naturally occurring cationic IgG.
Trépanier P; Aubin É; Bazin R
Clin Immunol; 2012 Mar; 142(3):383-9. PubMed ID: 22281428
[TBL] [Abstract][Full Text] [Related]
8. Mouse Schwann cells activate MHC class I and II restricted T-cell responses, but require external peptide processing for MHC class II presentation.
Meyer zu Hörste G; Heidenreich H; Mausberg AK; Lehmann HC; ten Asbroek AL; Saavedra JT; Baas F; Hartung HP; Wiendl H; Kieseier BC
Neurobiol Dis; 2010 Feb; 37(2):483-90. PubMed ID: 19914379
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of thymus-independent type 2 antigens on MHC class II-restricted antigen presentation: comparative analysis of carbohydrate structures and the antigen presenting cell.
González-Fernández M; Carrasco-Marín E; Alvarez-Domínguez C; Outschoorn IM; Leyva-Cobián F
Cell Immunol; 1997 Feb; 176(1):1-13. PubMed ID: 9070312
[TBL] [Abstract][Full Text] [Related]
10. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation.
Burgdorf S; Kautz A; Böhnert V; Knolle PA; Kurts C
Science; 2007 Apr; 316(5824):612-6. PubMed ID: 17463291
[TBL] [Abstract][Full Text] [Related]
11. Concerted antigen presentation by dendritic cells and B cells is necessary for optimal CD4 T-cell immunity in vivo.
Kleindienst P; Brocker T
Immunology; 2005 Aug; 115(4):556-64. PubMed ID: 16011524
[TBL] [Abstract][Full Text] [Related]
12. Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells.
Röhn TA; Schadendorf D; Sun Y; Nguyen XD; Roeder D; Langen H; Vogt AB; Kropshofer H
Eur J Immunol; 2005 Oct; 35(10):2826-39. PubMed ID: 16163671
[TBL] [Abstract][Full Text] [Related]
13. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
Ilkovitch D; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2004 Jun; 53(6):525-32. PubMed ID: 14730400
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.
Dembic Z; Schenck K; Bogen B
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2697-702. PubMed ID: 10706628
[TBL] [Abstract][Full Text] [Related]
15. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
16. Indirect activation of naïve CD4+ T cells by dendritic cell-derived exosomes.
Théry C; Duban L; Segura E; Véron P; Lantz O; Amigorena S
Nat Immunol; 2002 Dec; 3(12):1156-62. PubMed ID: 12426563
[TBL] [Abstract][Full Text] [Related]
17. Glycation of a food allergen by the Maillard reaction enhances its T-cell immunogenicity: role of macrophage scavenger receptor class A type I and II.
Ilchmann A; Burgdorf S; Scheurer S; Waibler Z; Nagai R; Wellner A; Yamamoto Y; Yamamoto H; Henle T; Kurts C; Kalinke U; Vieths S; Toda M
J Allergy Clin Immunol; 2010 Jan; 125(1):175-83.e1-11. PubMed ID: 19864011
[TBL] [Abstract][Full Text] [Related]
18. Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition.
Patel DM; Arnold PY; White GA; Nardella JP; Mannie MD
J Immunol; 1999 Nov; 163(10):5201-10. PubMed ID: 10553040
[TBL] [Abstract][Full Text] [Related]
19. Antigen presentation to naive CD4 T cells in the lymph node.
Itano AA; Jenkins MK
Nat Immunol; 2003 Aug; 4(8):733-9. PubMed ID: 12888794
[TBL] [Abstract][Full Text] [Related]
20. Tregitopes and impaired antigen presentation: Drivers of the immunomodulatory effects of IVIg?
Sordé L; Spindeldreher S; Palmer E; Karle A
Immun Inflamm Dis; 2017 Dec; 5(4):400-415. PubMed ID: 28560793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
